帕纳克斯人参对食后葡萄糖耐受性的时间依赖性影响. 一项针对健康中年参与者的随机对照研究
1Department of Process and Life Science Engineering, Division Food and Pharma, Lund University, Lund, Sweden.
Frontiers in nutrition
|March 9, 2026
概括
在饭前90分钟服用帕纳克斯人参可显著降低血糖和胰岛素水平. 帕纳克斯人参的摄入时间对于其调节葡萄糖的作用至关重要.
科学领域:
- 营养科学 营养科学
- 人体生理学 人体生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕纳克斯人参 (P. ginseng) 传统上用于改善血糖调节,但科学证据不一致.
- 对P.人参对血糖控制的影响的精确机制和最佳时间需要进一步研究.
研究的目的:
- 为了研究P.人参消费作为预装对食后葡萄糖和胰岛素反应的影响.
- 为了确定P.人参的摄入时间是否会影响其葡萄糖调节作用.
主要方法:
- 一个随机,双盲,交叉试验,涉及22名健康的中年成年人.
- 参与者在90分钟后,45分钟后或在标准化富含碳水化合物的早餐之前立即食用P.人参片 (32毫克总人参) 或安慰剂.
- 饭后血糖和胰岛素水平被测量了150分钟.
主要成果:
- 在饭前90分钟摄入P.人参可使葡萄糖iAUC降低29%,Ipeak降低26% (P<0.001).
- 在饭前45分钟食用P.人参,降低了15%的葡萄糖Ipeak (P <0.01) 和23%的胰岛素IAUC (P <0.01).
- 当P.人参在饭前立即服用时,没有观察到对葡萄糖或胰岛素的显著影响.
结论:
- 预加载时间对于最大限度地降低P. ginseng的降糖效果至关重要.
- 普丁人参显示出作为糖分管理的饮食策略的潜力,特别是在饭前45-90分钟食用时.
- 进一步的研究可以探索最佳剂量和特定的金氏化物配置文件,以提高疗效.
更多相关视频
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.8K
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
72.2K
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
718
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
718
Oral Hypoglycemic Agents: Glinides
785
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
785
Hypoglycemia and Glucagon
1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
Hormones Regulating Blood Glucose
7.9K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
7.9K
Glucose Homeostasis: Regulation of Blood Glucose
4.9K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
4.9K
Dipeptidyl Peptidase 4 Inhibitors
827
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
827
